



1637

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of **Roland Carlsson, et. al.**
Application No. 09/734,801
Attorney Docket No. EricPotter
Filed: December 12, 2000
For: METHOD FOR IN VITRO MOLECULAR
EVOLUTION OF PROTEIN FUNCTION
Examiner: Suryaprabha Chunduru
Group Art Unit: 1637

RECEIVED
JUN 04 2003
TECH CENTER 1600/2900

CERTIFICATE OF MAILING UNDER 37 C.F.R § 1.8(a)

I hereby certify that this Correspondence is being deposited on the date identified below with the United States Postal Service as first-class mail in an envelope properly addressed to COMMISSIONER FOR PATENTS, P.O. Box 1450, Alexandria, VA 22313-14500

5/29/03
Date of Certificate

Lyn C. Fischer
Lyn C. Fischer

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.97**

In compliance with the duty of disclosure set forth in 37 C.F.R. § 1.56, Applicants are submitting herewith a Form PTO-1449 and a copy of the references listed thereon. This Information Disclosure Statement is being filed more than three months after the filing date of this application, and after receipt of the first Official Action on the merits, but before receipt of a Final Official Action or a Notice of Allowance. Accordingly, the fee required under 37 C.F.R. 1.97(c) is enclosed. In the event the check is improper, or the fee calculation is in error, the Commissioner is authorized to charge any underpayment or credit any overpayment to the account of the undersigned attorneys, Account No. 04-1406. A duplicate copy of this sheet is enclosed.

In the opinion of the undersigned, the references submitted herewith are the most pertinent of which the undersigned is aware. However, no representation is made or intended that more pertinent references do not exist.


This submission is not an admission that the references listed on the attached Form PTO-1449 constitute prior art against the claims of this application.

The Examiner is respectfully requested to confirm receipt and consideration of the cited references by initialing and returning a copy of the attached Form PTO-1449 in accordance with MPEP §609.

Early and favorable consideration of this application is respectfully requested.

Respectfully submitted,

DANN, DORFMAN, HERRELL & SKILLMAN
A Professional Corporation
Attorneys for Applicant(s)


By 
Kathleen D. Rigaut, Ph.D., J.D.
PTO Registration No. 43,047

Telephone: (215) 563-4100

Facsimile: (215) 563-4044

Enclosures - Form PTO-1449

Copies of references listed on PTO - 1449


 INFORMATION DISCLOSURE STATEMENT	Complete if known	
	Application Number: 09/734,801	
	Filing Date: December 12, 2000	
	First Named Inventor: Roland Carlsson, et. al.	
	Group Art Unit: 1637	
Examiner Name: Suryaprabha Chunduru		RECEIVED JUN 04 2003 TECH CENTER 1600/2900
Attorney Docket Number: EricPotter		
SHEET 1 OF 2		

UNITED STATES PATENT DOCUMENTS				
EXAMINER'S INITIALS	CITE NO.	PATENT NUMBER	ISSUE DATE MM-DD-YYYY	FIRST NAMED INVENTOR
	A1	6,143,527	11-07-2000	Catherine J. Pachuk, et. al.

FOREIGN PATENT DOCUMENTS					
EXAMINER'S INITIALS	CITE NO.	DOCUMENT NUMBER	COUNTRY OR REGION	DATE OF PUBLICATION MM-DD-YYYY	FIRST NAMED INVENTOR OR APPLICANT
✓	B1	WO 98/01581	PCT	01-15-1998	Recombinant Biocatalysis, Inc.
✓	B2	WO 99/23236	PCT	05-14-1999	Diversa Corporation
✓	B3	WO 01/96551	PCT	12-20-2001	Diversa Corporation
✓	B4	WO 02/29032	PCT	04-11-2002	Diversa Corporation
	B5	WO 00/46344	PCT	08-10-2000	Diversa Corporation
✓	B6	WO 00/53744	PCT	09-14-2000	Diversa Corporation
✓	B7	WO 00/77262	PCT	12-21-2000	Diversa Corporation
✓	B8	WO 00/58517	PCT	10-05-2000	Diversa Corporation
✓	B9	WO 97/07205	PCT	02-27-1997	Novo Nordisk A/S
✓	B10	WO 97/07206	PCT	02-27-1997	Novo Nordisk A/S
✓	B11	WO 98/41623	PCT	09-24-1998	Novo Nordisk A/S
✓	B12	WO 98/41622	PCT	09-24-1998	Novo Nordisk A/S
✓	B13	WO 98/28416	PCT	07-02-1998	Novo Nordisk A/S
✓	B14	WO 00/72013	PCT	11-30-2000	The Penn State Research Foundation
✓	B15	WO 01/75158	PCT	10-11-2001	The Penn State Research Foundation
	B16	WO 96/05803	PCT	02-29-1996	Quest International B.V.
	B17	WO 01/34835	PCT	05-17-2001	Max-Planck Gesellschaft zur Förderung der Wissenschaften E.V., et. al.
	B18	WO 99/58661	PCT	11-18-1999	Diatech Pty. Ltd.

EXAMINER'S SIGNATURE		DATE CONSIDERED	
----------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP §609. Draw a line through citation if citation not in conformance and reference not considered. Include a copy of this form with next communication to applicant.

 INFORMATION DISCLOSURE STATEMENT	Complete if known	
	Application Number: 09/734,801	
	Filing Date: December 12, 2000	
	First Named Inventor: Roland Carlsson, et. al.	
	Group Art Unit: 1637	
Examiner Name: Suryaprabha Chunduru		Attorney Docket Number: EricPotter
SHEET 2 OF 2		

	B19	WO 02/16606	PCT	02-28-2002	Biomethodes
	B20	WO 00/09679	PCT	02-24-2000	Proteus (S.A.)
	B21	WO 00/34512	PCT	06-15-2000	Proteus (S.A.)

OTHER PRIOR ART - NON-PATENT DOCUMENTS		
EXAMINER'S INITIALS	CITE NO.	Include name of the author (in Capital Letters), title of the article (when appropriate), title of the item(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published

RECEIVED
 JUN 04 2003
 TECH CENTER 1600/2900

EXAMINER'S SIGNATURE		DATE CONSIDERED	
-------------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP §609. Draw a line through citation if citation not in conformance and reference not considered. Include a copy of this form with next communication to applicant.